Codice QR

Overexpression of KMT9α is associated with poor outcome in cholangiocarcinoma patients

Abstract Purpose The newly discovered histone methyltransferase KMT9 serves as an epigenetic regulator of carcinogenesis in various cancer entities. For the first time, we investigated the presence of KMT9α in cholangiocarcinoma, the association with histologic subtypes, and its impact on survival....

Descrizione completa

Salvato in:
Autori principali: Maximilian N. Kinzler, Eric Metzger, Rebecca Schulz, Katrin Bankov, Anna Ramos-Triguero, Falko Schulze, Steffen Gretser, Nada Abedin, Armin Wiegering, Stefan Zeuzem, Dirk Walter, Henning Reis, Roland Schüle, Peter J. Wild
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer 2025-05-01
Serie:Journal of Cancer Research and Clinical Oncology
Soggetti:
Biomarker
Cholangiocarcinoma
Surgical oncology
Lysine methyltransferase 9
KMT9α
Accesso online:https://doi.org/10.1007/s00432-025-06214-w
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi